1. In-hospital prognosis of first-ever noncardiogenic ischemic stroke in patients with and without indication for prestroke antiplatelet therapy: Chinese Stroke Center Alliance
- Author
-
Zixiao Li, Yilong Wang, Xingquan Zhao, Yongjun Wang, Xia Meng, Qi Zhou, Yunyun Xiong, Hongqiu Gu, Liping Liu, and Yu-Yuan Xu
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Stroke severity ,General Medicine ,Odds ratio ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Primary prevention ,Ischemic stroke ,medicine ,Original Article ,Observational study ,In patient ,cardiovascular diseases ,030212 general & internal medicine ,education ,business ,Stroke ,030217 neurology & neurosurgery - Abstract
BACKGROUND: It is unknown about the influence of prestroke antiplatelet use on early outcomes in patients with and without the indication. We aimed to evaluate the in-hospital prognosis of first-ever noncardiogenic ischemic stroke patients with and without indications of antiplatelet use for primary prevention. METHODS: This was a retrospective, observational study based on a prospective hospital-based registry (Chinese Stroke Center Alliance). Using the data with 436,660 first-ever noncardiogenic acute ischemic strokes recorded from Aug 1, 2015, to July 31, 2019, from 1,453 hospitals in China, we examined the associations between the indication for prestroke antiplatelet use and in-hospital clinical outcomes. RESULTS: Among 436,660 first-ever noncardiogenic ischemic stroke patients, 42,409 patients (9.7%) had a documented previous vascular indication and 394,251 (90.3%) did not. Compared to those without, patients with the indication were associated with increased prevalence of in-hospital morbid conditions, including stroke severity (OR 2.71; 95% CI: 2.62–2.81; P14 days (OR 1.16; 95% CI: 1.13–1.19; P
- Published
- 2021
- Full Text
- View/download PDF